Notably, the use of guideline-directed heart failure therapy (including ACE inhibitors, angiotensin receptor blockers, beta-blockers, mineralocorticoid receptor-antagonists) did not differ significantly between the finasteride treatment and the control group. Here, NR3C2 is linked to heart failure.